Sagimet Biosciences Advances FASN Inhibitor Trials for Acne and MASH, Reports Q2 Earnings

Sagimet Biosciences reported Q2 earnings with $135.5 million in cash and equivalents. The company announced progress in its clinical trials, including a successful Phase 3 trial for denifanstat in acne and the initiation of a Phase 1 trial for TVB-3567. R&D expenses increased to $22.6 million, contributing to a net loss of $28.6 million for the first half of 2025. Sagimet plans to initiate a Phase 1 trial for a combination therapy in the latter half of 2025.